FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2806362238> ?p ?o ?g. }

• W2806362238 abstract "Abstract Background Prompt, effective treatment of confirmed malaria cases with artemisinin-based combination therapy (ACT) is a cornerstone of malaria control. Maximizing adherence to ACT medicines is key to ensuring treatment effectiveness. Methods This open-label, randomized trial evaluated caregiver adherence to co-formulated artemether–lumefantrine (AL) and fixed-dose amodiaquine–artesunate (AQAS) in Sierra Leone. Children aged 6–59 months diagnosed with malaria were recruited from two public clinics, randomized to receive AL or AQAS, and visited at home the day after completing treatment. Analyses were stratified by site, due to differences in participant characteristics and outcomes. Results Of the 784 randomized children, 680 (85.6%) were included in the final per-protocol analysis (340 AL, 340 AQAS). Definite adherence (self-reported adherence plus empty package) was higher for AL than AQAS at both sites (Site 1: 79.4% AL vs 63.4% AQAS, odds ratio [OR] 2.16, compared to probable adherence plus probable or definite non-adherence, 95% confidence interval [CI] 1.34–3.49; p = 0.001; Site 2: 52.1% AL vs 37.5% AQAS, OR 1.53, 95% CI 1.00–2.33, p = 0.049). However, self-reported adherence (ignoring drug package inspection) was higher for both regimens at both sites and there was no strong evidence of variation by treatment (Site 1: 96.6% AL vs 95.9% AQAS, OR 1.19, 95% CI 0.39–3.63, p = 0.753; Site 2: 91.5% AL vs 96.4% AQAS, OR 0.40, 95% CI 0.15–1.07, p = 0.067). In Site 2, correct treatment (correct dose + timing + duration) was lower for AL than AQAS (75.8% vs 88.1%, OR 0.42, 95% CI 0.23–0.76, p = 0.004). In both sites, more caregivers in the AQAS arm reported adverse events (Site 1: 3.4% AL vs 15.7% AQAS, p < 0.001; Site 2: 15.2% AL vs 24.4% AQAS, p = 0.039). Conclusions Self-reported adherence was high for both AL and AQAS, but varied by site. These results suggest that each regimen has potential disadvantages that might affect adherence; AL was less likely to be taken correctly at one site, but was better tolerated than AQAS at both sites. Measuring adherence to anti-malarials remains challenging, but important. Future research should focus on comparative studies of new drug regimens, and improving the methodology of measuring adherence. Trial registration : Clinicaltrials.gov, NCT01967472. Retrospectively registered 18 October 2013, https://clinicaltrials.gov/ct2/show/NCT01967472" @default.
• W2806362238 created "2018-06-13" @default.
• W2806362238 creator A5016082976 @default.
• W2806362238 creator A5020242502 @default.
• W2806362238 creator A5026726987 @default.
• W2806362238 creator A5029384863 @default.
• W2806362238 creator A5032201964 @default.
• W2806362238 date "2018-06-04" @default.
• W2806362238 modified "2023-10-15" @default.
• W2806362238 title "Adherence to treatment with artemether–lumefantrine or amodiaquine–artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial" @default.
• W2806362238 cites W1638473988 @default.
• W2806362238 cites W1748374718 @default.
• W2806362238 cites W1806888623 @default.
• W2806362238 cites W1964487163 @default.
• W2806362238 cites W1967977548 @default.
• W2806362238 cites W1971919551 @default.
• W2806362238 cites W1972110417 @default.
• W2806362238 cites W1973152735 @default.
• W2806362238 cites W1987278539 @default.
• W2806362238 cites W2002346296 @default.
• W2806362238 cites W2007383122 @default.
• W2806362238 cites W2012134054 @default.
• W2806362238 cites W2019668483 @default.
• W2806362238 cites W2022498633 @default.
• W2806362238 cites W2050622314 @default.
• W2806362238 cites W2051920823 @default.
• W2806362238 cites W2055098113 @default.
• W2806362238 cites W2056448233 @default.
• W2806362238 cites W2056664774 @default.
• W2806362238 cites W2070610132 @default.
• W2806362238 cites W2074020970 @default.
• W2806362238 cites W2091649381 @default.
• W2806362238 cites W2097205415 @default.
• W2806362238 cites W2109295408 @default.
• W2806362238 cites W2111638000 @default.
• W2806362238 cites W2111983706 @default.
• W2806362238 cites W2125195525 @default.
• W2806362238 cites W2128483604 @default.
• W2806362238 cites W2135140437 @default.
• W2806362238 cites W2136945880 @default.
• W2806362238 cites W2139440519 @default.
• W2806362238 cites W2141398594 @default.
• W2806362238 cites W2145166645 @default.
• W2806362238 cites W2148667838 @default.
• W2806362238 cites W2151891585 @default.
• W2806362238 cites W2152137379 @default.
• W2806362238 cites W2153584506 @default.
• W2806362238 cites W2155441883 @default.
• W2806362238 cites W2162391545 @default.
• W2806362238 cites W2164108601 @default.
• W2806362238 cites W2166204244 @default.
• W2806362238 cites W2171031967 @default.
• W2806362238 cites W2171688296 @default.
• W2806362238 cites W2172064636 @default.
• W2806362238 cites W2188001005 @default.
• W2806362238 cites W2321229711 @default.
• W2806362238 cites W2423453378 @default.
• W2806362238 cites W2492847043 @default.
• W2806362238 cites W2530106721 @default.
• W2806362238 cites W2580949548 @default.
• W2806362238 cites W2595709181 @default.
• W2806362238 cites W2739329641 @default.
• W2806362238 cites W55019719 @default.
• W2806362238 doi "https://doi.org/10.1186/s12936-018-2370-x" @default.
• W2806362238 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5987409" @default.
• W2806362238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29866192" @default.
• W2806362238 hasPublicationYear "2018" @default.
• W2806362238 type Work @default.
• W2806362238 sameAs 2806362238 @default.
• W2806362238 citedByCount "17" @default.
• W2806362238 countsByYear W28063622382019 @default.
• W2806362238 countsByYear W28063622382020 @default.
• W2806362238 countsByYear W28063622382021 @default.
• W2806362238 countsByYear W28063622382022 @default.
• W2806362238 countsByYear W28063622382023 @default.
• W2806362238 crossrefType "journal-article" @default.
• W2806362238 hasAuthorship W2806362238A5016082976 @default.
• W2806362238 hasAuthorship W2806362238A5020242502 @default.
• W2806362238 hasAuthorship W2806362238A5026726987 @default.
• W2806362238 hasAuthorship W2806362238A5029384863 @default.
• W2806362238 hasAuthorship W2806362238A5032201964 @default.
• W2806362238 hasBestOaLocation W28063622381 @default.
• W2806362238 hasConcept C126322002 @default.
• W2806362238 hasConcept C142724271 @default.
• W2806362238 hasConcept C156957248 @default.
• W2806362238 hasConcept C162324750 @default.
• W2806362238 hasConcept C168563851 @default.
• W2806362238 hasConcept C185032368 @default.
• W2806362238 hasConcept C187212893 @default.
• W2806362238 hasConcept C203014093 @default.
• W2806362238 hasConcept C2776120307 @default.
• W2806362238 hasConcept C2776623344 @default.
• W2806362238 hasConcept C2776992834 @default.
• W2806362238 hasConcept C2778048844 @default.
• W2806362238 hasConcept C2778059366 @default.
• W2806362238 hasConcept C2778118209 @default.
• W2806362238 hasConcept C2778371730 @default.
• W2806362238 hasConcept C2778629330 @default.
• W2806362238 hasConcept C2780780316 @default.
• W2806362238 hasConcept C3018567284 @default.

• next